- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
A great-resolution molecular breast imaging technology called positron emission mammography (PEM) has demonstrated great accuracy in detecting breast cancer. The imaging radiotracer used in PEM, 18F-FDG, helps to pinpoint regions with higher glucose utilisation.
A nuclear medicine imaging technique called positron emission mammography (PEM) is used to identify or diagnose breast cancer. In contrast to PEM, which employs an injected positron emitting isotope and a special scanner to find breast tumours, mammography normally refers to x-ray imaging of the breast.
Breast tumour identification with PEM camera technology has been demonstrated to be more accurate than with whole-body PET/CT imaging. F-18 fluorodeoxyglucose positron emission tomography showing Grade III multifocal infiltrating ductal carcinoma.
PEM has an advantage over whole-body PET in that it can find tiny hypermetabolic lesions. Due to its higher spatial resolution, PEM can detect lesions that are less than 2 cm in size.
Positron Emission Mammography (PEM) is a type of imaging that increasingly concentrates on imaging the chest rather than the entire body.A box with an x-ray producing tube is what a mammography unit is. The machine is solely used for breast x-ray exams, and it has extra accessories to ensure that only the breast is exposed to radiation.
The Global positron emission mammography(PEM) market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
A newly designed PEM device for the detection of small breast cancer was created by the NIH. Due to its superior spatial resolution, positron emission mammography (PEM) has a higher detection sensitivity for breast cancer than whole-body positron emission tomography (PET).
A novel PEM device that offers a large field of vision and great resolution has been created. The praseodymium-doped lutetium aluminium garnet (Pr:LuAG) scintillation crystals used in this PEM device are unique.
The clinical utility of the recently developed PEM for the early identification of tiny breast cancer was compared to that of the traditional PET-computed tomography (PET/CT) in the current investigation. In this study, 82 patients with breast cancer of less than 20 mm (UICC T1), including 23 with T1a or T1b breast cancer of less than 10 mm, took part.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2026 Mobility Foresights Pvt Ltd. All rights reserved.
Developed with by ClousTech